Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06033261 · ClinicalTrials.gov registry record · Phase 1
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
A Phase 1 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 303
- Enrollment target
NCT06033261 is a Phase 1 study that has completed, run by ModernaTX. The registered enrollment target is 303 participants.
The verdict
NCT06033261, a Phase 1 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 303 participants
- Enrollment target
Study Summary
The purpose of this study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mRNA-1608 vaccine candidate.
Interventions
- BIOLOGICAL mRNA-1608
- BIOLOGICAL BEXSERO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2023-09-06 |
| Est. Completion | 2025-04-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06033261
The ClinicalTrials.gov registry entry for NCT06033261 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which mRNA-1608 is the first listed.
NCT06033261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06033261 about?
NCT06033261 is a clinical study titled "A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes". The purpose of this study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mRNA-1608 vaccine candidate.
What is the current status of trial NCT06033261?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 303 participants. The study started on 2023-09-06. Estimated completion is 2025-04-25.
What interventions are being tested in trial NCT06033261?
The interventions under investigation include: mRNA-1608 (BIOLOGICAL), BEXSERO (BIOLOGICAL).
Who is sponsoring clinical trial NCT06033261?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.